16 results about "Progestin" patented technology

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

Compositions and methods for the delivery of progestin hormones that have binding affinity to the Sex Hormone Binding Globulin (SHBG) are disclosed. The compositions combine such progestins with non-progestin SHBG ligands to displace at least part of the progestin from SHBG in the blood plasma, thereby increasing its bioavailability. Also disclosed are methods to modulate progestin and estrogen levels in the blood through the use of SHBG binding and displacement, to optimize the effectiveness of formulations for contraception and minimize the side effects and adverse events.

This utility model discloses a prostaglandin vaginal capsule forming machine, relating to the technical field of capsule forming machines. It includes a support plate, with a slurry forming machine for producing prostaglandin vaginal capsules mounted on the top rear end of the support plate. The slurry forming machine has external auxiliary components for cutting. These auxiliary components include a mounting bracket mounted on the support plate, located at the front of the slurry forming machine. This utility model uses a dual-axis motor to drive a movable bracket, which is limited by a positioning bracket. The movable bracket then drives a cutter to cut the capsule. Because the unloading plate and the cutter move in contact, the slurry adhering to the cutter is pushed off by the unloading plate. Furthermore, because the unloading plate is supported by a telescopic rod and a spring, it can slowly push the slurry, avoiding excessive pressure that could scatter the slurry or hinder subsequent capsule forming. This prevents the slurry from adhering to the outside of the cutter, thus avoiding affecting the feeding efficiency and cutting effect.

The present disclosure relates to a specific combination of a progestin and testosterone in a transdermal composition and usage thereof in a method for ensuring male contraception with more efficacy and less side effects.

1. The name of the design product: packing box (progestin soft capsule). 2. The use of the design product: the design product is used for packing of goods. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best shows the design points: perspective view.

A vaginal system for a female, including an outer ring layer having a first silicone polymer and a core having a second silicone polymer and a progestin. When the vaginal system is positioned in a vagina of the female, an amount of the progestin released per day from the vaginal system is from about 10 μg to about 150 μg during a steady state release period. The vaginal system has from about 10 mg to about 250 mg of the progestin. The vaginal system is configured to release the progestin in the vagina for up to about 365 days or up to about 24 months.

This invention belongs to the field of biomedical technology, specifically relating to the application of Danbie capsules in the preparation of products for treating endometriosis. This invention discovers that the combined use of Danbie capsules and progestins has a synergistic effect, with a superior intervention effect on endometrial stromal cells compared to a single component. Furthermore, this invention provides a traditional Chinese medicine-containing serum, the main medicinal components of which are quercetin and luteolin, which can effectively inhibit the growth and migration of endometrial stromal cells and induce apoptosis. This traditional Chinese medicine-containing serum is derived from Danbie capsules. Animal experiments have shown that Danbie capsules can inhibit the expression of AKT1 in endometrial tissue, and cell experiments have shown that the traditional Chinese medicine-containing serum can induce apoptosis of endometrial stromal cells, suggesting that the intervention effect of the traditional Chinese medicine Danbie capsules and its containing serum on endometrial stromal cells is related to AKT1 expression, providing an important insight into the relevant mechanism.

1. A drug delivery device for use in treating one or more menopausal symptoms in a subject, comprising intravaginal insertion of an indwelling drug delivery device into the subject, wherein the drug delivery device comprises an estrogen and a progestin, and further provides a baseline-adjusted steady-state plasma estrogen concentration in the subject of about 15 pg / mL to about 50 pg / mL.

The invention provides a pharmaceutical composition and application thereof in treatment of endometrial cancer, and relates to the technical field of biological medicine. It is found for the first time that combined use of the KDM1A inhibitor SP-2577 and MPA has a remarkable enhancement effect on inhibition of proliferation and cloning of endometrial cancer cells and promotion of cell apoptosis, and the KDM1A inhibitor SP-2577 and the MPA have a synergistic effect; meanwhile, an in-vivo experiment result further shows that compared with independent medication of MPA or SP-2577, combined use of the KDM1A inhibitor SP-2577 and MPA has more outstanding advantages in the aspect of inhibiting tumor growth. The invention provides the pharmaceutical composition consisting of the KDM1A inhibitor SP-2577 and the MPA, the pharmaceutical composition effectively improves the effect of treating the endometrial cancer by single progestational hormone, and an effective solution is provided for patients with low endometrial cancer progestational hormone sensitivity.

The invention discloses a group of isoprostaglandin metabolite markers for diagnosing male offspring reproductive function damage caused by exposure of nano-plastics during pregnancy and application of the isoprostaglandin metabolite markers. According to the present invention, it is found that after the parental generation is exposed to the nanometer plastic, the expression level of the prostate hormone metabolism marker 8-iso PGF3 [alpha] and / or 8-is-13, 14-dihydro-15-keto-PGF2 [alpha] related to reproductive injury in the male offspring is significantly up-regulated; therefore, 8-iso PGF3 alpha and / or 8-iso-13, 14-dihydro-15-keto-PGF2 alpha are / is taken as the metabolic marker, the influence of the male offspring reproductive injury caused by the nano plastic is disclosed, and a method is provided for diagnosis and evaluation of the male offspring reproductive injury caused by the nano plastic.

An HPC composition and method of treatment for the prevention of PTB and improved neonatal outcomes. The invention provides for a dosing regimen beginning as early as 14 weeks of fetal gestation and dosing regimens of a duration of as much as 25 weeks. The invention provides a high level of exogeneous progestin to endogenous progesterone when it is most needed. The instant invention consistently achieves active levels of HPC which achieve effectiveness. Exemplary dosing regimens comprise an oral administration of HPC in the range of 1,200 mg to 1600 mg, wherein the HPC is administered via a once a day, twice a day, or three times a day administration.

The invention provides a preparation method of a promestriene single crystal. The preparation method comprises the following steps: dissolving promestriene powder with isopropanol, filtering, transferring filtrate into a single crystal growth bottle, sealing the single crystal growth bottle with a plug, pricking the plug, and volatilizing under the conditions that the environment temperature is 30 + / -5 DEG C and the humidity is 50 + / -5% to obtain the promestriene single crystal. The invention provides a diffractable order single crystal for the first time, and the absolute configuration is directly analyzed through X-ray diffraction. The preparation method is simple to operate, only needs three steps of dissolving, filtering and volatilizing, and consumes 5-8 days. The prepared promestriene single crystal belongs to an orthorhombic crystal system and a P212121 space group, and the unit cell parameters of the promestriene single crystal are as follows: alpha is equal to 6.2174 (2), b is equal to 8.8913 (3), c is equal to 34.215 I (10), alpha is equal to 90 degrees, beta is equal to 90 degrees, gamma is equal to 90 degrees, and v is equal to 1891.44 (10).

The invention provides a traditional Chinese medicine composition for treating endometrial injury as well as a pharmaceutical preparation and application thereof, dandelion, sargentgloryvine stem, Chinese violet, patrinia herb for eliminating dampness and heat, artemisia anomala, radix bupleuri, corydalis tuber, szechwan chinaberry fruit for dredging Chong and Ren meridians, teasel and mistletoe for clearing and nourishing liver and kidney are selected, so that the dampness and heat are cleared, the Chong and Ren meridians are smooth in qi activity, the evil is removed, and the disease treatment is realized. A treatment result shows that the formula disclosed by the invention can improve the endometrial state by improving the blood flow of the uterine artery; tracking of pregnancy preparation information of a patient finds that the natural pregnancy rate of the patient treated by the traditional Chinese medicine composition within half a year is significantly higher than that of a control group (a female progestational hormone continuous therapy treatment group), the treatment thought of clearing and nourishing liver and kidney and dredging Chong and Ren channels can improve the intimal thickness of the patient, and it is possible to improve the intimal thickness of the patient by improving uterine artery blood perfusion. Finally, the endometrial receptivity is improved, and the pregnancy rate is increased. Therefore, the invention provides evidence-based basis and clinical guidance for the treatment of the recurrent abortion endometrial injury clinically.

To provide novel antagonists for progestin membrane receptors. [Solution] A compound represented by the following formula (A) or a salt thereof. TIFF2026089212000015.tif41149

The composition for use in the treatment of perimenopausal and post-menopausal symptomatology, comprising a combination of at least one GnRH receptor antagonist with at least one of: - an estrogenic hormone; - a progestin hormone - a selective modulator of estrogen hormone receptors.